Research summary

The page describes the listed 30 mg retatrutide pen as a prefilled research device and gathers its composition, storage information and batch documentation. Specifications and compatibility must be checked against the current product lot and device documentation. Lilly describes retatrutide as investigational; clinical trial findings do not validate this separate device or define its handling.[6] [7]

Summary revised November 1, 2026. This editorial update does not constitute a new literature review.

30mg total 300 clicks 0.1mg nominal increment Documentation-led calibration For Research Use Only

What Is the Retatrutide Pen Format?

The retatrutide pen is a prefilled liquid research format with a nominal 30mg content and 300-click device scale. Unlike a lyophilised vial, it does not require a reconstitution step. The nominal scale is a product specification; current lot and device documentation control the actual dispensing calibration and compatible laboratory accessories.

Retatrutide (LY3437943) is Eli Lilly’s investigational triple agonist of the GIP, GLP-1 and glucagon receptors. Lilly says it has not been approved by any regulatory agency, and Lilly plans to submit retatrutide for US approval in Q1 2027.[6][7]

This guide documents hardware identity, composition, storage and evidence sources. It does not translate published trial schedules into product-use instructions or provide priming, injection, accessory-selection or mg-to-click guidance.

Published Phase 2 and Phase 3 trials used protocol-controlled administration by study teams.[1][3] Those clinical procedures are reported as historical evidence and do not establish a handling protocol for a Remy Research research product.

Evidence and context

The 30mg retatrutide pen is a prefilled research device containing 30mg total across a nominal 300-click device scale. Composition, storage and batch proof are documented here. Dispensing, accessory compatibility and handling must follow the current lot/device documentation and an authorised institutional laboratory SOP; this page does not provide priming, injection, administration, titration or personal-use instructions.

Additional context

Scope note: this guide covers documented device specifications, storage, batch proof and research-handling boundaries, including how the pen differs from lyophilised vial formats. It does not provide a clinical schedule, administration procedure, or product-quantity calculation.

How Does Retatrutide Work on GLP-1, GIP and Glucagon Receptors?

Retatrutide is an investigational triple receptor agonist from Eli Lilly: a single molecule that activates three hormone receptors, the glucose-dependent insulinotropic polypeptide (GIP) receptor, the GLP-1 receptor and the glucagon receptor. In published clinical research, GLP-1 receptor activity is linked to glucose-dependent insulin release, slower gastric emptying and decreased appetite. GIP receptor activity is studied for how it adds to those GLP-1 effects, the basis of dual agonist compounds such as tirzepatide.

Glucagon receptor activity is the third arm. It is studied for energy expenditure and liver fat metabolism, which is why retatrutide also appears in fatty liver disease research. These findings describe the molecule in trials; they do not describe this pen or how to handle it. For the full receptor picture, see the GLP-1, GIP and glucagon mechanism guide and the retatrutide profile.

What Are the Pen Specifications and Pen Needles?

The retatrutide 30mg pen is a prefilled research device. The specification rows below separate nominal composition and scale from the documentation that controls laboratory handling.

Specification Detail
Format Prefilled Pen
Total Content 30mg retatrutide
Total Clicks 300 clicks
Nominal material increment 0.1mg per scale increment
Dispensing calibration Use current lot and device documentation
Intended use In-vitro laboratory research only
Accessory compatibility Controlled by current device documentation and institutional SOP
Storage (unopened) 2–8°C (refrigerated)
Storage (in use) Refrigerated (2–8°C) — return after each use

The device scale is a product specification, not an administration schedule. Do not infer a use protocol from the nominal content or click count.

What Controls Research Handling?

The pen is a prefilled research format. Handling, dispensing calibration, compatible laboratory accessories, storage limits, and disposal must follow the current lot documentation, device documentation, and an authorised institutional laboratory SOP. Remy Research does not provide priming, needle-selection, injection, administration, or personal-use instructions.

Published retatrutide trials used protocol-controlled subcutaneous administration by study teams. That historical fact is reported as clinical evidence only and does not establish a use procedure for a research-use product.

Which Sources Control the Device Record?

Use the current product specification and batch documentation for composition and verification, and the current lot/device documentation plus institutional SOPs for laboratory handling. Published clinical-trial schedules belong to the cited study records and are not converted here into product clicks, quantities, or administration steps.

The certificate of analysis (COA) for the Remedium Research 30mg pen is the Janoshik HPLC report for batch RETP002.[2] Write the batch number (some labels call it the lot number) from the pen’s label into the storage log next to that COA reference, so every storage note traces back to a named batch.

How Does a Pen Differ from a Lyophilised Vial?

A prefilled pen and a lyophilised vial are different laboratory formats. The pen is supplied as a sealed liquid device; the vial is a dry research material whose preparation and handling depend on its batch documentation and the institution's SOP. This page does not rank formats by personal convenience or translate either format into administration instructions.

Current ZPHC-labelled pen references include the Retatrutide AQ 30mg pen and Retatrutide 60mg dual-chamber pen. Lyophilised ZPHC references are listed separately as the 15mg vial and the 10mg, 20mg, 40mg, 60mg, and 120mg multi-vial kits. Each product page carries its own live price, stock, format, and evidence boundary.

Storage follows each pen’s own label. The ZPHC dual-chamber pen keeps dry powder and sterile water in separate chambers, so its peptide is not in solution during transit and storage; the storage guidance on its original box applies. Genovare’s retatrutide AQ pens are premixed aqueous pens, stored as the Genovare pack label directs. That includes RETAKLIK 2.0, Genovare’s pen that combines 30mg of retatrutide with 5mg of cagrilintide.

Factor Prefilled pen Lyophilised vial
Supplied as Sealed liquid in a prefilled device Dry powder in a sealed vial
Before first use No reconstitution step Reconstitution under the institution’s SOP
Scale Nominal 300-click scale on the 30mg pen; current device documentation controls calibration Set by the laboratory’s own preparation SOP
Storage 2–8°C, never frozen, protected from light As stated on the lot documentation
Batch proof Lot COA, for example RETP002 Lot COA

For the 30mg pen itself, see the Remedium Research 30mg retatrutide pen; for the lyophilised format, see the 10mg and 40mg retatrutide vials. To convert a pen’s nominal click scale into listed material, use the retatrutide pen clicks to mg calculator; for vial units, use the retatrutide calculator. For retatrutide cost by format, see the Dubai pricing guide, and to buy retatrutide pens or vials for laboratory and research purposes, see Retatrutide UAE.

How Should a Retatrutide Pen Be Stored in the UAE?

Knowing how to store a retatrutide pen protects peptide integrity and keeps research results consistent. Retatrutide degrades when exposed to heat, light, or repeated freeze-thaw cycles, so the cold chain matters from delivery onward.

Does a Retatrutide Pen Need to Be Kept Chilled?

Yes. Proper storage for the 30mg pen, as its product page lists, is 2–8°C with the cold chain maintained, no freezing and protection from light. The pen holds retatrutide as a liquid solution, so it must never be frozen. That band is standard refrigerator temperature. It is also the long-term storage condition (5°C ± 3°C) that the ICH Q1A(R2) stability guideline uses for products meant for a refrigerator, and for those products the guideline sets 25°C at 60% relative humidity as the accelerated condition.[8] Accelerated conditions are exaggerated storage settings chosen to speed up degradation, so for a refrigerated product, ordinary room temperature already counts as stress.

Before First Use: Injection Sites

After First Use

So what happens if a retatrutide pen gets warm? Brief room-temperature exposure during use is expected, but sustained heat above 30°C or direct sun accelerates degradation — a pen left in a hot car or shipped without a cold chain should be treated as compromised. For underlying peptide degradation kinetics, see the peptide stability and storage guide. In hot climates such as the UAE — where ambient temperatures regularly exceed 45°C — temperature-controlled transport and refrigerated storage are non-negotiable. The delivery policy covers Dubai dispatch and transport, and the broader UAE peptide catalog lists every research compound currently in stock.

How Long Does a Retatrutide Pen Last in the Fridge?

How long a pen keeps in the fridge is set by its own label and lot documentation, with the pen held at 2–8°C and never frozen. Expiry differs by brand, format and batch, and day counts quoted online for other pen products do not carry over to this one.

Retatrutide Pen Storage in UAE Heat: Transport and Receipt

Remy Research sends products that need refrigeration in insulated cold-chain packaging intended to keep them at 2–8°C during delivery, with a live tracking link once the order is dispatched. Dubai orders placed before 4 PM arrive the same day, and orders outside Dubai placed before 12 PM (noon) arrive the next day; the delivery page lists the weekend exceptions. The weak point is the time between the doorstep and the fridge.

When Should a Pen Be Set Aside?

Treat a pen as compromised and note it in the storage log if any of these apply:

The science behind these checks comes from general peptide and protein research; none of it was measured on this pen. Freezing exposes a protein solution to low temperature, freeze-concentration and ice crystal formation, the three chief stresses that can cost it biological activity.[9] Light can photo-oxidise protein residues such as tryptophan, tyrosine, phenylalanine and cysteine.[10] Peptides in solution can also self-associate into amorphous aggregates or fibrils, and temperature and agitation are among the factors that influence it.[11] A visual inspection catches only gross changes. It cannot confirm peptide content, which is what the batch documentation records.

Where Is Retatrutide in Clinical Trials?

Retatrutide is still undergoing clinical trials and is not an approved medicine anywhere. In the pivotal Phase 3 TRIUMPH-1 obesity trial (topline reported by Lilly on May 21, 2026; published in the New England Journal of Medicine on September 29, 2026), participants on the 12 mg dose had a mean 28.3% reduction in body weight at 80 weeks on the efficacy estimand, or 25.0% under the treatment-regimen estimand.[12] TRIUMPH-2 and TRIUMPH-3, the latter an 80-week weight trial in people with established cardiovascular disease, reported positive topline results on 23 July 2026.[7] Eli Lilly plans to submit retatrutide for US approval in the first quarter of 2027; no submission or PDUFA date exists yet.[6]

Commonly reported adverse events in the trials were gastrointestinal. These are results for Lilly’s drug product under trial protocols and do not validate this research pen. Follow the TRIUMPH trial tracker, the approval status page and the side-effects review for updates.

The research format lists 30mg total retatrutide across a nominal 300-click device scale. Batch proof and current product specifications should be checked against the product and COA pages.
No. Remy Research supplies the material for in-vitro laboratory research only. The page does not provide priming, needle-selection, injection, administration, titration, or personal-use instructions.
The current lot documentation, device documentation, and an authorised institutional laboratory SOP control dispensing calibration, compatible accessories, handling and disposal. These details must not be inferred from the nominal content alone.
Keep the product refrigerated at 2–8°C, protected from light, and do not freeze it. Follow the current lot and device documentation for any additional storage limits.
Yes. The 30mg research pen is stored at 2–8°C with the cold chain maintained, protected from light and never frozen. Remy Research ships it in insulated cold-chain packaging, and it should go into the refrigerator as soon as it arrives.
As long as its own label and lot documentation state, held at 2–8°C and never frozen. Expiry differs by brand, format and batch.

Our Research Standards for Research Peptides

This article cites peer-reviewed studies, FDA filings, and ClinicalTrials.gov data. All claims are cross-referenced against primary sources. We update articles when new trial data or regulatory decisions are published. Read our editorial policy →

RP
Editorial Review

Editorial Board, Remy Research

The Remy Research Editorial Board reviews research articles covering GLP-1 receptor agonists, triple agonists, and the obesity drug pipeline. Its review checks sources, numerical claims, scientific and regulatory-status accuracy, and compliance wording.

About the editorial team →

Sources

  1. Jastreboff AM, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526. nejm.org
  2. Janoshik Analytical — Certificate of Analysis, Batch RETP002. HPLC purity: 99.262%. remyresearch.com/coa/retp002/
  3. Eli Lilly. TRIUMPH Clinical Trial Program for Retatrutide. clinicaltrials.gov ↩
  4. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529–544. doi.org/10.1016/S0140-6736(23)01053-X
  5. Urva S, Coskun T, Loh MT, et al. LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial. Lancet. 2022;400(10366):1869–1881. PMID 36354040. doi.org/10.1016/S0140-6736(22)02033-5
  6. Eli Lilly and Company. What to know about retatrutide. lilly.com, September 29, 2026. lilly.com
  7. Eli Lilly and Company. Lilly’s triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. Press release, July 23, 2026. investor.lilly.com
  8. ICH. Q1A(R2) Stability Testing of New Drug Substances and Products. Step 4 version, 6 February 2003. Storage conditions for products intended for storage in a refrigerator, and the glossary definition of accelerated testing. database.ich.org
  9. Bhatnagar BS, Bogner RH, Pikal MJ. Protein stability during freezing: separation of stresses and mechanisms of protein stabilization. Pharm Dev Technol. 2007;12(5):505–523. PMID 17963151. doi.org/10.1080/10837450701481157
  10. Kerwin BA, Remmele RL Jr. Protect from light: photodegradation and protein biologics. J Pharm Sci. 2007;96(6):1468–1479. PMID 17230445. doi.org/10.1002/jps.20815
  11. Zapadka KL, Becher FJ, Gomes Dos Santos AL, Jackson SE. Factors affecting the physical stability (aggregation) of peptide therapeutics. Interface Focus. 2017;7(6):20170030. PMID 29147559. doi.org/10.1098/rsfs.2017.0030
  12. Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity (TRIUMPH-1). N Engl J Med. Published online September 29, 2026. doi:10.1056/NEJMoa2604169. doi.org/10.1056/NEJMoa2604169